

# Xiao Jun Wang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10438308/publications.pdf>

Version: 2024-02-01

11  
papers

110  
citations

1478505

6  
h-index

1281871

11  
g-index

11  
all docs

11  
docs citations

11  
times ranked

219  
citing authors

#	ARTICLE	IF	CITATIONS
1	Minimal Clinically Important Difference of the Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF) for Fatigue Worsening in Asian Breast Cancer Patients. <i>Journal of Pain and Symptom Management</i> , 2018, 55, 992-997.e2.	1.2	31
2	Economic burden of chemotherapy-induced febrile neutropenia in patients with lymphoma: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 94, 201-212.	4.4	20
3	Costs associated with febrile neutropenia in solid tumor and lymphoma patients – an observational study in Singapore. <i>BMC Health Services Research</i> , 2014, 14, 434.	2.2	13
4	Cost-effectiveness analysis of a universal mass vaccination program with a PH1D-CV 2+1 schedule in Malaysia. <i>Cost Effectiveness and Resource Allocation</i> , 2017, 15, 17.	1.5	12
5	Psychometric properties and measurement equivalence of the Multidimensional Fatigue Syndrome Inventory- Short Form (MFSI-SF) amongst breast cancer and lymphoma patients in Singapore. <i>Health and Quality of Life Outcomes</i> , 2018, 16, 20.	2.4	9
6	Routine Primary Prophylaxis for Febrile Neutropenia with Biosimilar Granulocyte Colony-Stimulating Factor (Nivestim) or Pegfilgrastim Is Cost Effective in Non-Hodgkin Lymphoma Patients undergoing Curative-Intent R-CHOP Chemotherapy. <i>PLoS ONE</i> , 2016, 11, e0148901.	2.5	7
7	Optimizing Symptoms and Management of Febrile Neutropenia among Cancer Patients: Current Status and Future Directions. <i>Current Oncology Reports</i> , 2017, 19, 20.	4.0	5
8	The prognostic performance of adding patient-reported outcomes to the MASCC risk index to identify low-risk febrile neutropenia patients with solid tumors and lymphomas. <i>Supportive Care in Cancer</i> , 2017, 25, 2815-2822.	2.2	5
9	Psychometric Properties of the Functional Assessment of Cancer Therapy – Neutropenia in Asian Cancer Patients With Chemotherapy-Induced Neutropenia. <i>Journal of Pain and Symptom Management</i> , 2016, 52, 428-436.	1.2	3
10	Role of Procalcitonin in Differentiating between Infectious and Noninfectious Fevers among Patients with Lymphoma. <i>Pharmacotherapy</i> , 2017, 37, 908-915.	2.6	3
11	Therapeutic Use of Filgrastim for Established Febrile Neutropenia Is Cost Effective Among Patients With Solid Tumors and Lymphomas. <i>Clinical Therapeutics</i> , 2017, 39, 1161-1170.	2.5	2